What Is a Comprehensive Guide to Mild Cognitive Impairment Treatment Options?

Which MCI treatments the neurology guideline actually backs, who qualifies for the new amyloid drugs, and what to fix first.

A comprehensive guide to mild cognitive impairment treatment options starts with one honest fact: no drug is approved to treat MCI itself, and the strongest evidence points to exercise, cognitive activity, and fixing the medical problems that worsen thinking. The exception is a narrow one — people whose MCI is caused by Alzheimer's disease with confirmed amyloid in the brain now have two infused drugs available to them. Mild cognitive impairment means measurable decline in memory or thinking that friends, family, or testing can detect, but that has not yet stolen a person's ability to manage daily life. That gap between "noticeable" and "disabling" is what makes treatment decisions here different from dementia care.

Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.

Table of Contents

Why no pill treats MCI itself

The American Academy of Neurology reviewed the evidence in its 2018 practice guideline update on mild cognitive impairment and found no high-quality evidence supporting any pharmacologic treatment for the condition. No medication holds FDA approval for MCI. The guideline goes further on the drugs most often floated.

Clinicians may choose not to offer cholinesterase inhibitors — donepezil, rivastigmine, galantamine, the drugs used in Alzheimer's dementia — for MCI. If a clinician does prescribe one off-label, the guideline directs them to discuss the lack of evidence with the patient first. That conversation is a requirement, not a courtesy. Practically, this means a prescription offered at an MCI visit deserves a question: what is the evidence for this in MCI specifically? A doctor following the guideline will say there isn't strong evidence, and explain why they're suggesting it anyway.

The AAN guideline recommends that clinicians advise regular exercise for people with MCI, based on six-month trials suggesting it possibly improves cognitive measures. Materials accompanying the guideline framed the advice as twice-weekly exercise. Cognitive training is offered as a possible benefit alongside it. The largest recent test of the structured version of this advice is U.S.

POINTER, published in JAMA on July 28, 2025. Among 2,111 sedentary adults aged 60 to 79 with added risk factors, a two-year program combining exercise, diet, cognitive and social activity, and cardiovascular monitoring improved global cognition 0.243 standard deviations per year faster than a self-guided program. Read that result carefully. The gain showed up in global cognition, not in memory specifically — and the comparison group was also doing something, just less structured. The practical reading: a supported, scheduled program beats good intentions, and both beat nothing.

Treating what else is making thinking worse

The guideline directs clinicians to assess for and treat modifiable contributors to cognitive symptoms. This is the part of MCI care that most often goes undone, and it is where the clearest wins live.

AAN's 2025 quality measure set operationalizes it with measures on avoiding anticholinergic medications and educating care partners. Things worth raising at an MCI appointment:.

  • A full medication review, specifically for anticholinergic drugs — common in older-adult prescriptions for bladder symptoms, sleep, allergies, and depression
  • Thyroid function, vitamin B12, and other reversible metabolic causes
  • Sleep problems, especially untreated sleep apnea
  • Depression, anxiety, and other behavioral or neuropsychiatric symptoms, which the guideline names as treatment targets in their own right
  • Hearing and vision, which affect how someone performs on testing and in conversation

Anti-amyloid drugs, and who actually qualifies

For the subset of people whose MCI is caused by Alzheimer's disease with confirmed amyloid pathology, there is now drug treatment. The FDA approved donanemab, sold as Kisunla, on July 2, 2024, and the approval announcement states that treatment should be initiated at the mild cognitive impairment or mild dementia stage. Donanemab is a once-monthly 30-minute infusion. In TRAILBLAZER-ALZ 2, which enrolled 1,736 participants, Eli Lilly reported that it slowed cognitive and functional decline by 22% overall and by up to 35% in the least-advanced subgroup at 18 months, and reduced amyloid plaque by about 84%. Lecanemab, sold as Leqembi, is the other option for this group, and its risks are specific and documented.

Its label carries a boxed warning for amyloid-related imaging abnormalities — brain swelling (ARIA-E) and brain bleeding (ARIA-H). The label requires ApoE ε4 genetic testing before starting, because people with two copies of that variant have higher rates of symptomatic and serious ARIA. Risk also rises in people who already have microhemorrhages or superficial siderosis on brain imaging. Two gates stand between an MCI diagnosis and either drug: confirmed amyloid pathology, and a risk profile that survives the imaging and genetic workup. Most people with MCI will not clear both.

What the numbers say about where MCI goes

MCI is common and becomes more so with age. AAN's guidance cites prevalence above 6% among people in their 60s and above 37% among those aged 85 and older, so these decisions reach a very large population. Prognosis is not a single path. AAN-cited figures put the risk of progressing to dementia at roughly 7.5% in the first year after an MCI diagnosis and about 20% by year three.

Some people with MCI stay stable, and some revert to normal cognition. That variability is the main limit on any treatment claim, including the favorable ones. A person who improves may have improved anyway, and a trial result measured over 18 or 24 months is measuring a slope, not a cure. It also argues for repeat assessment rather than a single verdict: the diagnosis that fits this year may not be the one that fits next year.

Frequently Asked Questions

Should I ask for a cholinesterase inhibitor for MCI?

You can ask, but the AAN guideline says clinicians may choose not to offer these drugs for MCI, and must discuss the absent evidence before prescribing one off-label.

How do I know if my MCI is caused by Alzheimer's disease?

It requires testing for amyloid pathology. That confirmation is the entry requirement for donanemab and lecanemab, which are approved for the Alzheimer's-caused subset, not for MCI generally.

Does exercise have to be intense to count?

The guideline's recommendation rests on six-month trials, and the advice accompanying it was framed as twice-weekly exercise — a schedule you can keep matters more than intensity.


You Might Also Like

HelpDementia.com

Dementia, Alzheimer's, Caregiving & Healthy Aging Guidance

© 2026 HelpDementia.com. All rights reserved.

Educational information only. It is not medical advice and does not replace care from a qualified clinician.